https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53765 Wed 28 Feb 2024 15:59:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50571 Wed 28 Feb 2024 15:53:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53918 Wed 28 Feb 2024 15:40:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53995 Wed 28 Feb 2024 15:22:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29970 Wed 24 Nov 2021 15:50:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46451 Wed 23 Nov 2022 14:17:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41167 Wed 21 Jun 2023 15:55:59 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32527 Wed 17 Nov 2021 16:31:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21992 Bacillus species were identified compared with healthy controls. PCR analyses revealed increased rates of detection of potentially pathogenic bacteria with Haemophilus influenzae detection associated with higher sputum levels of NE and IL-1β, while Streptococcus pneumoniae was more common in male ex-smokers with emphysema and a deficit in diffusion capacity. Conclusion: Non-pathogenic and pathogenic bacteria were altered in the sputum of patients with COPD. These observations highlight the potential to identify treatment and management strategies that both target specific bacterial pathogens and restore the microbial balance, which may lead to reductions in inflammation and subsequent improvements in lung health.]]> Wed 17 Nov 2021 16:31:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17148 Wed 11 Apr 2018 17:15:05 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13589 Wed 11 Apr 2018 16:34:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18585 Wed 11 Apr 2018 15:35:46 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25075 Wed 11 Apr 2018 12:27:25 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13950 Wed 11 Apr 2018 11:45:39 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13988 Wed 11 Apr 2018 10:50:22 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34714 Wed 10 Nov 2021 15:05:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24433 Wed 09 Feb 2022 15:59:14 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33733 Wed 09 Feb 2022 15:56:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50859 Wed 09 Aug 2023 10:13:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33179 1 < 80% predicted to those with an FEV₁ > 80% predicted after bronchodilator use. In the population with an FEV₁< 80%, analysis was further stratified based on smoking history. Results: Omalizumab treatment markedly improved asthma control and health-related quality of life in all populations assessed based on the Asthma Control Questionnaire and Asthma Quality of Life Questionnaire scores. Omalizumab treatment did not improve lung function (FEV₁, FVC, or FEV₁/FVC ratio) in populations that were enriched for asthma-COPD overlap (diagnosis of COPD or FEV₁ < 80%/ever smokers). Conclusions: Our study suggests that omalizumab improves asthma control and health-related quality of life in individuals with severe allergic asthma and overlapping COPD. These findings provide real-world efficacy data for this patient population and suggest that omalizumab is useful in the management of severe asthma with COPD overlap.]]> Wed 04 Sep 2019 09:48:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41407 Wed 03 Aug 2022 11:03:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37411 Wed 02 Mar 2022 14:26:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36722 Wed 02 Mar 2022 14:26:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46634 p < 0.05) and controls. In bronchiectasis and COPD, lower levels/better patterns of ST accumulation, as well as higher LIPA volume were associated with better clinical characteristics. These associations may be mediated by airflow limitation. Conclusions: The discordance between engagement in ST volume versus ST patterns highlights the importance of accounting for both these different yet complementary metrics. ST and LIPA are low-intensity activities associated with important clinical characteristics in people with chronic respiratory diseases. Trial registration: Not applicable.]]> Tue 29 Nov 2022 10:26:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54427 Tue 27 Feb 2024 13:53:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51997 Tue 26 Sep 2023 11:07:44 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21583 Tue 26 Jun 2018 11:28:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19319 55 years) with obstructive airway disease and healthy controls (N=56) underwent inhaler technique assessment, skin allergy testing, venepuncture, fractional exhaled nitric oxide (FENO) and gas diffusion measurement, exercise testing, sputum induction, and questionnaire assessment. They then completed an assessment burden questionnaire across five domains: difficulty, discomfort, pain, symptoms and test duration. Results: Test perception was generally favourable. Induced sputum had the greatest test burden perceived as being more difficult (mean 0.83, P=0.001), associated with more discomfort (mean 1.3, P<0.001), more painful (0.46, P=0.019), longer test duration (0.84, P<0.001) and worsening symptoms (0.55, P=0.001) than the questionnaires. FENO had a more favourable assessment but was assessed to be difficult to perform. Inhaler technique received the most favourable assessment. Conclusions: Older adults hold favourable perceptions to a range of tests that they might encounter in the course of their care for airway disease. The newer tests of sputum induction and FENO have some observed difficulties, in particular sputum induction. The results of this study can inform current practice by including details of the test and its associated adverse effects when conducting the test, as well as providing clear explanations of the utility of tests and how the results might aid in patient care.]]> Tue 26 Jun 2018 11:28:14 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54355 Tue 20 Feb 2024 16:20:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51001 Tue 15 Aug 2023 12:06:35 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52770 Tue 14 Nov 2023 15:04:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49105 Tue 14 Nov 2023 14:40:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47085 Tue 13 Dec 2022 16:35:23 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53621 Tue 12 Dec 2023 15:19:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38811 Tue 08 Feb 2022 14:30:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39063 Tue 03 May 2022 11:38:18 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54560 Thu 29 Feb 2024 10:27:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35593 Thu 28 Oct 2021 13:03:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31397 IL1R1, IL1R2, and IL1RN), and signaling molecules (IRAK2, IRAK3, and PELI1), were measured in sputum using real-time quantitative polymerase chain reaction. Mediators were compared between the frequent (≥2 exacerbations in the 12 months) and infrequent exacerbators, and the predictive relationships investigated using receiver operating characteristic curves and area under the curve (AUC) values. Results: Of the 95 participants, 89 completed the exacerbation follow-up, where 30 participants (n=22 COPD, n=8 asthma) had two or more exacerbations. At the baseline visit, expressions of IRAK2, IRAK3, PELI1, and IL1R1 were elevated in participants with frequent exacerbations of both asthma and COPD combined and separately. In the combined population, sputum gene expression of IRAK3 (AUC=75.4%; P<0.001) was the best predictor of future frequent exacerbations, followed by IL1R1 (AUC=72.8%; P<0.001), PELI1 (AUC=71.2%; P<0.001), and IRAK2 (AUC=68.6; P=0.004). High IL-1 pathway gene expression was associated with frequent prior year exacerbations and correlated with the number and severity of exacerbations. Conclusion: The upregulation of IL-1 pathway mediators is associated with frequent exacerbations of obstructive airway disease. Further studies should investigate these mediators as both potential diagnostic biomarkers predicting at-risk patients and novel treatment targets]]> Thu 28 Oct 2021 13:03:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39670 Thu 28 Jul 2022 08:10:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45193 Thu 27 Oct 2022 14:56:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44829 Thu 27 Oct 2022 10:15:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34913 Thu 27 Jan 2022 15:59:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31999 Thu 27 Jan 2022 15:58:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46415 Thu 24 Nov 2022 13:56:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49460 1000 mg prednisolone-equivalent cumulatively are likely to have serious side effects and adverse outcomes. Patient perspectives emphasize the detrimental impacts of OCS-related side effects such as weight gain, insomnia, mood disturbances and skin changes. Improvements in asthma control and prevention of exacerbations can be achieved by improved inhaler technique, adherence to therapy, asthma education, smoking cessation, multidisciplinary review, optimized medications and other strategies. Recently, add-on therapies including novel biological agents and macrolide antibiotics have demonstrated reductions in OCS requirements. Harm reduction may also be achieved through identification and mitigation of predictable adverse effects. OCS stewardship should entail greater awareness of appropriate indications for OCS prescription, risk–benefits of OCS medications, side effects, effective add-on therapies and multidisciplinary review. If implemented, OCS stewardship can ensure that clinicians and patients with asthma are aware that OCS should not be used lightly, while providing reassurance that asthma can be controlled in most people without frequent use of OCS.]]> Thu 18 May 2023 12:40:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36371 Thu 17 Feb 2022 09:31:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29745 9/L vs 0.15×10⁹/L; P<0.0001). Blood eosinophils correlated with both the percentage (ρ=0.535; P<0.0001) and number of sputum eosinophils (ρ=0.473; P<0.0001). Absolute blood eosinophil count was predictive of sputum eosinophilia (area under the curve =0.76, 95% confidence interval [CI] =0.67–0.84; P<0.0001). At a threshold of ≥0.3×10/L (specificity =76%, sensitivity =60%, and positive likelihood ratio =2.5), peripheral blood eosinophil counts enabled identification of the presence or absence of sputum eosinophilia in 71% of the cases. A threshold of ≥0.4×10⁹/L had similar classifying ability but better specificity (91.7%) and higher positive likelihood ratio (3.7). In contrast, ≥0.2×10⁹/L offered a better sensitivity (91.1%) for ruling out sputum eosinophilia. There was a good agreement between two measurements of blood eosinophil count over a median of 28 days (intraclass correlation coefficient =0.8; 95% CI =0.66–0.88; P<0.0001). Conclusion: Peripheral blood eosinophil counts can help identify the presence or absence of sputum eosinophilia in stable COPD patients with a reasonable degree of accuracy.]]> Thu 17 Feb 2022 09:29:13 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31150 Thu 17 Feb 2022 09:28:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33710 Thu 17 Feb 2022 09:25:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33707 Thu 13 Jan 2022 10:32:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48870 Thu 13 Apr 2023 12:48:32 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49314 Thu 11 May 2023 14:39:45 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35398 0.05), and similar pulmonary and extrapulmonary characteristics. The associations between extrapulmonary variables and HRQoL did not differ according to diagnosis (all interactions p > 0.05). Greater anxiety and depressive symptoms, fewer steps/day and greater systemic inflammation were statistically associated with poorer HRQoL in both diseases (p < 0.05). Lower isometric leg strength in severe asthma, and greater Charlson Comorbidity Index in bronchiectasis were also associated with poorer HRQoL (p < 0.05). In the multivariable regression model performed in the combined disease groups, anxiety and depression, steps/day, systemic inflammation and isometric leg strength remained independently associated with HRQoL. Associations between extrapulmonary characteristics and SGRQ domains were stronger for the activity and impact domains, than symptoms. Conclusion: In severe asthma and bronchiectasis, extrapulmonary features including physical activity and leg strength have a significant impact on HRQoL, especially within the activity and impact domains. These features should be considered as part of the assessment of these conditions, and they may represent additional treatment targets to improve HRQoL.]]> Thu 09 Dec 2021 11:03:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47317 Thu 06 Jul 2023 13:59:45 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32622 Thu 03 Feb 2022 12:18:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46840 Thu 01 Dec 2022 15:50:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8465 Sat 24 Mar 2018 08:42:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:9395 Sat 24 Mar 2018 08:39:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7886 Sat 24 Mar 2018 08:35:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14580 Sat 24 Mar 2018 08:22:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14652 Sat 24 Mar 2018 08:19:13 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12974 Sat 24 Mar 2018 08:16:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11323 Sat 24 Mar 2018 08:12:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19572 Sat 24 Mar 2018 07:58:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17923 Sat 24 Mar 2018 07:56:23 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17917 55 years) (n = 100) with an OAD underwent a multidimensional assessment (MDA) involving questionnaires, clinical assessments, physiological measurements and biomarkers. Results: the assessment identified a mean (SD) of 11.3 (2.5) clinical management issues and 3.1 (1.8) comorbid conditions per participant. Common problems were: airways hyper-responsiveness (80%); airway inflammation (74%); activity limitation (74%) and systemic inflammation (60.5%). The number and type of issues were similar irrespective of a diagnosis of asthma or COPD (P = 0.2). The degree of health status impairment correlated significantly with the number of clinical management issues detected (r = 0.59; P < 0.0001). Conclusions: older people with OAD experience multiple clinical issues that adversely impact their health status. The number and type are similar irrespective of diagnosis. This MDA identifies significant clinical issues that may not be addressed in a diagnosis centred approach suggesting that a multidisciplinary approach is necessary when assessing and managing older people with OAD.]]> Sat 24 Mar 2018 07:56:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19120 Sat 24 Mar 2018 07:55:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19123 55 years) with OADs who underwent a multidimensional assessment at baseline and 4 years which involved spirometry, 6-min walk distance (6MWD), assessments of health status (Saint George's Respiratory Questionnaire, SGRQ), comorbidity, and serum and sputum biomarkers. All-cause mortality and respiratory hospitalisation during the follow-up period were recorded. Clinical outcomes were compared between basal and final visits, and changes in clinical outcomes were compared among asthma, COPD and asthma-COPD overlap groups. Associations between clinical parameters, biomarkers and prognosis were examined. Results: After a median follow-up of 4.2 years, outcome data were available for 75 (75.8%) patients. There were 16 (16.2%) deaths. The BODE index predicted all-cause mortality in older people with OADs. While spirometry, 6MWD and SGRQ deteriorated significantly over the 4 years, there was significant heterogeneity in the longitudinal changes in these clinical outcomes. Participants with COPD had a significant decline in FEV1 (p = 0.003), SGRQ (p = 0.030) and 6MWD [decline of 75.5 (93.4) m, p = 0.024]. The change in 6MWD was lower in the asthma-COPD overlap group. Airflow reversibility was associated with a reduced decline in 6MWD. Conclusion: COPD patients had a poor prognosis compared with asthma and asthma-COPD overlap patients. The BODE index is a useful prognostic indicator in older adults with OADs. Both airway disease diagnosis and BODE index warrant specific attention in clinical practice.]]> Sat 24 Mar 2018 07:55:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18331 Sat 24 Mar 2018 07:52:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28283 Sat 24 Mar 2018 07:41:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29214 Sat 24 Mar 2018 07:36:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28982 Sat 24 Mar 2018 07:29:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26966 Sat 24 Mar 2018 07:26:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4797 Sat 24 Mar 2018 07:20:40 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22677 Sat 24 Mar 2018 07:12:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37810 Mon 31 Jan 2022 15:14:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52861 100, one contributing to meta‐analysis), mean age range 27 to 54 years). We identified one ongoing study and three studies awaiting classification. One study was synthesised narratively, and another involved participants specifically with asthma‐COPD overlap. Most programmes were outpatient‐based, lasting from three to four weeks (inpatient) or eight to 12 weeks (outpatient). Education or self‐management components included breathing retraining and relaxation, nutritional advice and psychological counselling. One programme was specifically tailored for people with severe asthma. Pulmonary rehabilitation compared to usual care may increase maximal oxygen uptake (VO2 max) after programme completion, but the evidence is very uncertain for data derived using mL/kg/min (MD between groups of 3.63 mL/kg/min, 95% confidence interval (CI) 1.48 to 5.77; 3 studies; n = 129) and uncertain for data derived from % predicted VO2 max (MD 14.88%, 95% CI 9.66 to 20.1%; 2 studies; n = 60). The evidence is very uncertain about the effects of pulmonary rehabilitation compared to usual care on incremental shuttle walk test distance (MD between groups 74.0 metres, 95% CI 26.4 to 121.4; 1 study; n = 30). Pulmonary rehabilitation may have little to no effect on VO2 max at longer‐term follow up (9 to 12 months), but the evidence is very uncertain (MD −0.69 mL/kg/min, 95% CI −4.79 to 3.42; I2 = 49%; 3 studies; n = 66). Pulmonary rehabilitation likely improves functional exercise capacity as measured by 6‐minute walk distance, with MD between groups after programme completion of 79.8 metres (95% CI 66.5 to 93.1; 5 studies; n = 529; moderate certainty evidence). This magnitude of mean change exceeds the minimally clinically important difference (MCID) threshold for people with chronic respiratory disease. The evidence is very uncertain about the longer‐term effects one year after pulmonary rehabilitation for this outcome (MD 52.29 metres, 95% CI 0.7 to 103.88; 2 studies; n = 42). Pulmonary rehabilitation may result in a small improvement in asthma control compared to usual care as measured by Asthma Control Questionnaire (ACQ), with an MD between groups of −0.46 (95% CI −0.76 to −0.17; 2 studies; n = 93; low certainty evidence); however, data derived from the Asthma Control Test were very uncertain (MD between groups 3.34, 95% CI −2.32 to 9.01; 2 studies; n = 442). The ACQ finding approximates the MCID of 0.5 points. Pulmonary rehabilitation results in little to no difference in asthma control as measured by ACQ at nine to 12 months follow‐up (MD 0.09, 95% CI −0.35 to 0.53; 2 studies; n = 48; low certainty evidence). Pulmonary rehabilitation likely results in a large improvement in quality of life as assessed by the St George's Respiratory Questionnaire (SGRQ) total score (MD −18.51, 95% CI −20.77 to −16.25; 2 studies; n = 440; moderate certainty evidence), with this magnitude of change exceeding the MCID. However, pulmonary rehabilitation may have little to no effect on Asthma Quality of Life Questionnaire (AQLQ) total scores, with the evidence being very uncertain (MD 0.87, 95% CI −0.13 to 1.86; 2 studies; n = 442). Longer‐term follow‐up data suggested improvements in quality of life may occur as measured by SGRQ (MD −13.4, 95% CI −15.93 to −10.88; 2 studies; n = 430) but not AQLQ (MD 0.58, 95% CI −0.23 to 1.38; 2 studies; n = 435); however, the evidence is very uncertain. One study reported no difference between groups in the proportion of participants who experienced an asthma exacerbation during the intervention period. Data from one study suggest adverse events attributable to the intervention are rare. Overall risk of bias was most commonly impacted by performance bias attributed to a lack of participant blinding to knowledge of the intervention. This is inherently challenging to overcome in rehabilitation studies. Authors' conclusions: Moderate certainty evidence shows that pulmonary rehabilitation is probably associated with clinically meaningful improvements in functional exercise capacity and quality of life upon programme completion in adults with asthma. The certainty of evidence relating to maximal exercise capacity was very low to low. Pulmonary rehabilitation appears to confer minimal effect on asthma control, although the certainty of evidence is very low to low. Unclear reporting of study methods and small sample sizes limits our certainty in the overall body of evidence, whilst heterogenous study designs and interventions likely contribute to inconsistent findings across clinical outcomes and studies. There remains considerable scope for future research.]]> Mon 30 Oct 2023 10:01:13 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38401 Mon 29 Jan 2024 17:48:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53947 Mon 22 Jan 2024 16:56:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46276 Mon 14 Nov 2022 15:31:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46274 Mon 14 Nov 2022 15:28:10 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46221 Mon 14 Nov 2022 12:04:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36441 Mon 04 May 2020 13:05:04 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47750 Fri 27 Jan 2023 09:56:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48632 Fri 24 Mar 2023 10:57:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40118 Fri 22 Jul 2022 13:48:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40097 Fri 22 Jul 2022 13:41:19 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52682 Fri 20 Oct 2023 09:44:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49505 Fri 19 May 2023 14:07:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44511 Fri 14 Oct 2022 09:11:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46081 adj], 18.10 and 19.17, respectively) and mechanical ventilation (RR_adj , 2.56 and 5.71, respectively) than did cluster 1. Individuals in cluster 3 had an extended length of hospital stay (11 days), increased hospitalization direct costs (13,481.57 Chinese Yuan), and a higher risk of ICU admission (RR_adj , 2.14) than individuals in clusters 1 and 2. The decision tree assigned 90.8% of the participants correctly. Conclusions: We identified 3 phenotypes with differential clinical and inflammatory characteristics associated with in-hospital adverse outcomes. These new phenotypes might have important and clinically relevant implications for the management of patients hospitalized for AEs.]]> Fri 11 Nov 2022 15:15:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46094 1 and FVC. Trends towards similar clinical associations with elevated MCs were observed in a paucigranulocytic subpopulation (n = 15) lacking airway eosinophilia or neutrophilia. Receiver operator characteristic (ROC) analysis showed peripheral blood eosinophil (PBE) count predicted elevated sputum eosinophils and basophils, but not MCs. Conclusions and Clinical Relevance: Sputum MCs are elevated in asthma, and their measurement may be useful as they relate to key clinical features of asthma (spirometry, asthma control, AHR). PBE count did not predict airway MC status, suggesting direct measurement of airway MCs by sensitive methods such as flow cytometry should be further developed.]]> Fri 11 Nov 2022 11:01:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22673 Fri 11 Jun 2021 13:31:32 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30102 Fri 11 Jun 2021 13:30:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38377 Fri 10 Sep 2021 12:38:35 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51535 Fri 08 Sep 2023 12:31:27 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54670 Fri 08 Mar 2024 11:32:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33714 Fri 07 Dec 2018 16:47:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37118 Fri 03 Dec 2021 10:32:20 AEDT ]]>